Liquidia Corporation Common Stock vs Global X Defense Tech ETF — how do they compare? Liquidia Corporation Common Stock trades at $33.75 (market cap $3.04B), while Global X Defense Tech ETF trades at $59.99 (market cap $6.34B). The key difference: Global X Defense Tech ETF is far larger — about 2.1× Liquidia Corporation Common Stock's market cap, and Liquidia Corporation Common Stock is more actively traded (21,111,778 versus 1,295,513). Which is the better fit depends on your goals — on Pluang, investors hold Liquidia Corporation Common Stock for 0 Days and Global X Defense Tech ETF for 45 Days on average.
| LQDA | SHLD | |
|---|---|---|
Market Cap | $3.04B | $6.34B |
Volume | 21,111,778 | 1,295,513 |
Sector | Health | Sector/Thematic |
52-Week High | $91.03 | $78.02 |
52-Week Low | $22.02 | $58.20 |
Typical Hold Time | 0 Days | 45 Days |
Enterprise Value | $2.94B | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
SHLD (Global X Defense Tech ETF) trades at $59.34, down 0.82% on the day amid bearish technical signals. The ETF faces selling pressure with 13 bearish moving average signals versus zero bullish. Recent institutional buying activity from Focus Financial Network and Balefire LLC indicates professional interest in defense technology exposure. The fund focuses on emerging defense technologies and cybersecurity with global diversification beyond traditional U.S. defense names.
Defense sector tailwinds from increased global military spending provide growth catalysts, though valuation metrics remain unavailable. Geopolitical tensions and European rearmament initiatives support the investment thesis, but sector concentration and political budget risks require monitoring. The ETF's technology focus differentiates it from traditional defense funds but carries execution risks in emerging defense technologies.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Liquidia Corporation is a biopharmaceutical company that develops therapies for rare cardiopulmonary diseases, including YUTREPIA, an inhaled treprostinil powder for pulmonary hypertension built on its PRINT technology.
Read more on LQDA →SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →